The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Boston Scientific Announces Schedule for Heart Rhythm Society Scientific Sessions

Thursday, May 03, 2012

Boston Scientific Announces Schedule for Heart Rhythm Society Scientific Sessions08:30 EDT Thursday, May 03, 2012NATICK, Mass., May 3, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces its schedule of major events and sponsored research at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, which takes place May 9 ? 12 in Boston.  The scheduled clinical presentations will provide new insights for physicians who treat patients with heart disorders including sudden cardiac arrest, atrial fibrillation and heart failure.  Schedule of Events All times are EDT, with events to be held at the Boston Convention Center unless otherwise indicated.Tuesday, May 8 (Pre-Conference)Allied Health Symposium.  Boston Scientific will host "Essentials of CRM Therapy and Patient Management" chaired by Melanie T. Gura, MSN, in the Grand Ballroom of the Hyatt Regency Boston from 7:30 a.m. to 3:00 p.m.  This one-day symposium is designed to provide allied health providers with contemporary information on current therapies, challenges and the management of pacemaker, defibrillator and heart failure patients.  The event will include faculty members Ann M. Anderson NP, Jennifer E. Cummings, MD, Shephal Doshi, MD, and Mary Orencole, NP. Wednesday, May 9Results from the ALTITUDE Study: Clinical Outcomes After Implantation of Single Versus Dual Coil Implantable Cardioverter Defibrillator Leads.  Jonathan Hsu, MD, will present results from the ALTITUDE Study during a featured poster session and reception from 5:30 p.m. to 7:00 p.m. in the Exhibit Hall.  The ALTITUDE clinical program analyzes outcomes data from patients monitored by Boston Scientific's LATITUDE® Patient Management system.Findings from the SMART-AV Trial: The Comparison of Electrogram-based AV Optimization and Nominal AV Delay in the Context of Electrical Dysysnchrony.  Michael Gold, MD, PhD, FHRS, will present findings from the SMART-AV Trial during a featured poster session and reception from 5:30 p.m. to 7:00 p.m. in the Exhibit Hall.  SMART-AV is a randomized three-armed trial designed to investigate the effects of optimizing AV delay timing in heart failure patients receiving CRT-D therapy.24th Annual Michel Mirowski Sudden Cardiac Arrest Symposium and Award Presentation.  Boston Scientific will sponsor the 24th Annual Michel Mirowski Sudden Cardiac Arrest Symposium and Award Presentation from 6:15 p.m. to 9:00 p.m. in the Grand Ballroom of the Westin Boston Waterfront Hotel.  Moderated by last year's award recipient, Silvia G. Priori, MD, PhD, the event will begin with an opening from the company's chief medical officer for cardiac rhythm management Kenneth Stein, MD, followed by recognition of past award recipients as well as the legacy of Michel Mirowski, MD.  The ceremony will then honor this year's Mirowski Award recipient, William G. Stevenson, MD.  Two presentations led by Dr. Stevenson and Leslie A. Saxon, MD, will focus on therapies for ventricular tachycardia and new frontiers for the management of large patient populations using remote data collection and cloud computing.Thursday, May 10EP Fellows Billing and Coding Seminar.  The company will sponsor an Electrophysiology (EP) Fellows Breakfast Roundtable from 6:30 a.m. to 7:30 a.m. in the Essex Ballroom North of the Westin Copley Hotel.  Hosted by Brian Le, MD, the event will provide education on billing and coding for EP procedures and is targeted to Fellows transitioning into practice this summer.Friday, May 11Late-Breaking Session: Analysis of the ASA Plavix Registry.  Vivek Reddy, MD, will present the first formal analysis of results from the ASA Plavix Registry (ASAP) during a late-breaking abstract session from 8:00 a.m. to 9:30 a.m. in the Ballroom West.  This multi-center, prospective non-randomized study enrolled 150 patients to assess the performance of the WATCHMAN® LAA Closure Device in non-valvular atrial fibrillation subjects for which warfarin therapy was contraindicated.  The company plans to issue a press release announcing study results in conjunction with the presentation. Conference attendees are invited to view Boston Scientific's latest cardiac rhythm management and electrophysiology products at booth #1033 in the main exhibit hall.  About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.   Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and our business plans.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A ? Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A ? Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:Steven Campanini508-652-5740 (office)214-546-5034 (cell) during the conferenceMedia RelationsBoston Scientific Corporationsteven.campanini@bsci.com Sean Findlen617-520-7268  (office)Media RelationsWeber Shandwicksfindlen@webershandwick.comSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporationinvestor_relations@bsci.com  SOURCE Boston Scientific Corporation